TECENTRIQ + Avastin® (bevacizumab) Offers a Same-Day Dosing Schedule
A combination therapy with consistent, q3w infusions 1,8
Dosing information for Avastin is based on the
IMbrave150 trial; TECENTRIQ was administered q3w in IMbrave150.
Visualization of vials is illustrative and does not represent actual
vial usage.
IV=intravenous; q2w=every 2 weeks; q3w=every 3
weeks; q4w=every 4 weeks.
- TECENTRIQ should be administered first, followed by Avastin
- Administer the initial infusion of TECENTRIQ over 60
minutes; if the first infusion is tolerated, all subsequent
infusions may be delivered over 30 minutes
- If
Avastin is discontinued, TECENTRIQ can be administered as 840 mg
q2w, as 1200 mg q3w, or as 1680 mg q4w
- Do not
administer TECENTRIQ as an IV push or bolus
- Do not co-administer other drugs through the same IV line
- Administer Avastin as an IV infusion
- First
infusion of Avastin: administer infusion over 90 minutes
- Subsequent infusions: administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated
- Refer to the Avastin Prescribing Information for Avastin dosage modifications for specific adverse reactions. No dose reductions for Avastin are recommended
Select Important Safety Information for Avastin 8
- An evaluation for the presence of varices is recommended within 6 months of initiation of Avastin in patients with HCC
- There is lack of clinical data to support the safety of Avastin
in patients with history or risk of variceal bleeding
Dosage modifications from the TECENTRIQ Prescribing Information 1*
| Adverse reaction | Severity of adverse reaction† | Dosage modifications |
|---|---|---|
| Pneumonitis | Grade 2 |
Withhold dose until grade 1 or resolved and corticosteroid
dose is less than or equal to prednisone 10 mg per day (or
equivalent) |
| Grade 3 or 4 | Permanently discontinue | |
| Hepatitis in patients with cancers other than
HCC | AST or ALT >3 and ≤8 times ULN or total
bilirubin >1.5 and ≤3 times ULN | Withhold dose
until grade 1 or resolved and corticosteroid dose is less than
or equal to prednisone 10 mg per day (or equivalent) |
| AST or ALT >8 times ULN or total bilirubin >3 times
ULN | Permanently discontinue | |
| Hepatitis in patients with HCC |
| Withhold dose until grade 1 or resolved
and corticosteroid dose is less than or equal to prednisone 10
mg per day (or equivalent) |
| AST or ALT increases to more than 10 times the ULN or total
bilirubin increases to more than 3 times the ULN |
Permanently discontinue | |
| Colitis or diarrhea | Grade 2 or
3 | Withhold dose until grade 1 or resolved and
corticosteroid dose is less than or equal to prednisone 10 mg
per day (or equivalent) |
| Grade 4 | Permanently discontinue | |
| Endocrinopathies‡
| Grade 2, 3, or 4 | Withhold dose
until grade 1 or resolved and clinically stable on hormone
replacement therapy |
| Other immune-mediated adverse reactions involving
a major organ | Grade 3 | Withhold
dose until grade 1 or resolved and corticosteroid dose is less
than or equal to prednisone 10 mg per day (or equivalent) |
| Grade 4 | Permanently discontinue | |
| Infections | Grade 3 or 4 |
Withhold dose until grade 1 or resolved |
| Infusion-related reactions | Grade 1
or 2 | Interrupt or slow the rate of
infusion |
| Grade 3 or 4 | Permanently discontinue | |
| Persistent grade 2 or 3 adverse reaction (excluding
endocrinopathies) | Grade 2 or 3 adverse reaction
that does not recover to grade 0 or 1 within 12 weeks after last
TECENTRIQ dose | Permanently discontinue |
| Inability to taper corticosteroid | Inability to
reduce to less than or equal to prednisone 10 mg per day (or
equivalent) within 12 weeks after last TECENTRIQ dose | Permanently discontinue |
| Recurrent grade 3 or 4 adverse reaction |
Recurrent grade 3 or 4 (severe or life-threatening) adverse
reaction | Permanently discontinue |
ALT=alanine aminotransferase; AR=adverse
reaction; AST=aspartate aminotransferase; HCC=hepatocellular
carcinoma; ULN=upper limit of normal.
*Refer to the
Avastin Prescribing Information
for dosage modifications and AR management.
†Graded per National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0.
‡Including, but not limited to, hypophysitis, adrenal
insufficiency, hyperthyroidism, and type 1 diabetes mellitus.